Marfan syndrome (MFS) is a systemic disorder of connective tissue caused by mutations in FBN1, the gene encoding fibrillin-1.
1 Cardiovascular disease, mainly aortic root dilation and aortic dissection, is the leading cause of mortality in MFS. Although early diagnosis and refined medical and surgical management have improved median cumulative probability of survival from approximately 40 to 70 years, individuals with MFS continue to have high morbidity and early mortality. 2 Transforming growth factor β (TGF-β) recently emerged as a potential mediator in the pathogenesis of MFS. 3 The current hypothesis is that a deficiency of extracellular fibrillin-1 causes failure of matrix sequestration of the TGF-β large latent complex with consequent excessive TGF-β activation and signaling, resulting in the pleiotropic MFS manifestations including developmental emphysema, myxomatous valve disease, skeletal muscle myopathy, and aortic root aneurysm. [3] [4] [5] [6] Studies in an Fbn1-targeted mouse model of MFS with aortic disease similar to that seen in humans showed that treatment with losartan, an angiotensin II receptor blocker, normalized aortic root growth and aortic wall architecture and that these improvements correlated with reduced TGF-β activity. 5 The National Heart, Lung, and Blood Institute (NHLBI)-funded Pediatric Heart Network designed a clinical trial to compare aortic root growth and other short-term cardiovascular outcomes in children and young adults with MFS randomized to receive losartan or atenolol, a β-blocker, which is the current standard of therapy at most centers. 7 The primary aim of this trial is to compare the effect of atenolol therapy with that of losartan therapy on the rate of aortic root growth over 3 years. We report here the characteristics of the screened population and enrolled subjects. A detailed description of the echocardiographic methods and echocardiographic characteristics of the enrolled subjects is being reported separately. 8 
Methods

Screening and randomization protocol
The design of this trial has been reported. 7 In brief, individuals 6 months to 25 years of age who met the original Ghent criteria 9 and had a body surface area-adjusted aortic root diameter z-score N3.0 were eligible for inclusion (Table I) . The study was designed to include subjects with this degree of aortic dilation at the time of enrollment because these individuals may be more likely than those with less aortic root dilation to show a treatment effect within the 3-year time frame of this study. Similarly, we excluded subjects with severe aortic dilation (≥5 cm) because they would likely withdraw before 3 years because of the need for surgery. To evaluate the effect of growth on change in z-score, we compared younger children who were still growing to older teenagers and young adults who were expected to have achieved final height at the time of study entry (≥16 years for males and ≥15 years for females). 10 The study protocol was approved by the institutional review board or institutional ethics board at each participating center, and informed consent was obtained from the patient or a parent or legal guardian before trial enrollment.
The study design included a multitiered screening, consent, and randomization process summarized in Figure 1 . Revised diagnostic criteria for MFS were published after initiation of this trial. 11 After completion of trial enrollment, we retrospectively compared the original and revised Ghent diagnostic criteria in the enrolled subjects and screened population. Nearly all the randomized subjects (603 of 608) and nonrandomized patients eligible for consent (42/43), all of whom had an aortic Flowchart of Pediatric Heart Network Marfan trial screened population. Abbreviations: LDS, Loeys-Dietz syndrome; SGS, ShprintzenGoldberg syndrome. a , The most common exclusion criterion at this stage of the screening process (not mutually exclusive) was having an aortic root diameter z-score ≤3 (71%), followed by indication of a prior aortic surgery or dissection or aortic surgery planned within 6 months (10%) and intolerance to angiotensin receptor blocker, angiotensin-converting enzyme inhibitor, or β-blocker (10%). A relatively small proportion of ineligible patients indicated therapeutic usage of angiotensin-converting enzyme inhibitor, β-blocker, or calcium-channel blockers (6%), inability to complete study procedures (6%), current or planned pregnancy (3%), aortic root dimension N5 cm (2%), and diabetes or renal dysfunction (1%). root diameter z-score N3.0, satisfied both the original and revised criteria.
Echocardiograms were performed under a standardized protocol and interpreted centrally by investigators blinded to treatment arm. Aortic root diameter was measured at the sinuses of Valsalva at its maximum dimension in systole, from inner edge to inner edge, in the parasternal long-axis view, 12 and body surface area-adjusted aortic root diameter z-score was calculated. 13 
Statistical methods
Weight, height, and body mass index (BMI) z-scores were derived from 2000 CDC Growth Charts. 14 Data are shown as mean ± SD, median (interquartile range), or n (%). Baseline demographic and clinical characteristics are not statistically different between treatment arms (P N .2) with the exception of positive endocrine history (P = .007). ⁎ In subjects who reported a family history of MFS.
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Results
Screening and randomization
Subjects were enrolled from January 2007 to February 2011 ( Figure 1 ). The extremely high consent rate (97%) did not allow a robust comparison of randomized subjects to fully eligible patients who were not randomized solely because of lack of consent. However, a comparison of randomized subjects (n = 608) to all nonrandomized patients (n = 43) who met Ghent criteria showed no significant differences in baseline characteristics (data not shown).
Baseline characteristics of the randomized cohort
The mean age at randomization was 11.2 years, 60% of subjects were male, and 25% of subjects were older teenagers and young adults who were expected to have achieved their final height at the time of randomization (Table II) . 10 Most of the subjects were b18 years of age (85%).
By design of the trial, all subjects had aortic root dilation and, therefore, met the major Ghent criterion for the cardiovascular system. The median aortic root diameter z-score was 4.0 (IQR 3.4-4.9) ( Table II) .
The most prevalent major criterion after the cardiovascular system was family or genetic history (76%, Figure 2 ), although FBN1 status was unknown in 56% of subjects (Table II) . A family history of MFS (as defined by Ghent criteria) was reported in 62% of subjects, with 35% of those subjects reporting 1 relative, 44% reporting 2 relatives, and 21% reporting ≥3 relatives with MFS (Table II) . Roughly a third of subjects with a family history of MFS also reported a family history of aortic dissection, and over half of subjects with a family history of MFS also reported a family history of aortic surgery.
Approximately half of the subjects met the major Ghent criteria for the skeletal or ocular systems (Figure 2 ). Fortysix percent of subjects met 2 major Ghent criteria, and 42% met 3 major criteria (Table II) . Imaging for dural ectasia varied widely by site (0%-49%); among those with imaging (n = 95), the prevalence of dural ectasia was 34%.
Most subjects (57%) reported prior usage of β-blockers at any time before the trial, whereas relatively few reported prior use of other antihypertensive medications. Only 3% of subjects reported prior use of angiotensin receptor blockers.
Neurodevelopmental conditions, mainly learning disabilities, attention deficit disorder, and/or hyperactivity, were reported in 19%. Psychiatric disorders, mainly depression and anxiety, were reported in 6%.
As expected, the subjects, in general, were thin and tall, as indicated by their weight, height, and BMI z-scores (Table III) . Specifically, BMI was 1 SD below normal, and height was, on average, 2 SDs above normal. The median arm span-to-height ratio was normal (1.03), and the median upper-to-lower segment ratio was 0.89. Most subjects (60%) had an abnormally reduced upperto-lower segment ratio; young children (≤6 years) were much more likely to have a reduced ratio (online Appendix B Supplemental Table I ).
Baseline demographic, clinical, and anthropometric characteristics (Table II and Table III) did not differ by assigned treatment arm (P N .2) with the exception of reported endocrine disorders (P = .007); the number of subjects reporting an endocrine disorder was small (n = 7).
Gender differences
Among those with a family history of MFS, a family history of aortic surgery was more common in females than males (71% vs 47%, P b .001) (Figure 3 ). The prevalence of mitral valve prolapse (MVP) and measurable (mild or more) mitral regurgitation (MR) was higher Prevalence of Ghent criteria in aggregate and by treatment arm. The prevalence of Ghent criteria, both major and involvement of organ systems, is shown. Prevalence of organ system involvement is calculated in subjects who do not meet major criteria in the respective organ system, with the exception of cardiovascular involvement. Because all subjects had aortic root dilation and, therefore, met the major criterion for the cardiovascular system, cardiovascular involvement indicates the prevalence of additional minor cardiovascular criteria of MVP and dilated main pulmonary artery in all randomized subjects. among female subjects (MVP: females 45% vs males 33%, P = .006, MR: females 25% vs males 13%, P b .001). A history of neurodevelopmental disorders requiring therapy was more common in males than in females (24% vs 12%, P b .001). These associations with gender were not modified by age at randomization (gender by age interaction P N .1). Excluding anthropometric measurements, other characteristics, including aortic root diameter z-score, did not differ between females and males (online Appendix B Supplemental Table II) .
Age effects
Aortic root diameter z-score was not dependent on age (online Appendix B Supplemental Table I ). Prior administration of β-blockers was more common in older subjects (P b .001). As expected, older subjects were also more likely to report a positive history of cardiovascular and psychiatric disorders (P ≤ .006). Although older subjects met a higher number of major Ghent criteria and were more likely to meet major criteria in the skeletal system and dura specifically, the prevalence of ectopia lentis was not dependent on age (Figure 4) . Older subjects were also more likely to show involvement of the pulmonary system and skin.
Aortic root diameter z-score
We examined the associations of quartiles of aortic root diameter z-score at randomization with other baseline characteristics (online Appendix B Supplemental Table  III) . Subjects with higher aortic root diameter z-scores were more likely to have other cardiovascular involvement (MVP and/or dilated main pulmonary artery, P = .006). In contrast, subjects with aortic root diameter z-scores in the first quartile (aortic root diameter z-score ≤3.42) were more likely to have a family history of MFS than subjects with larger aortic root diameter z-scores (75% vs 57%, P b .001). Aortic root diameter z-score was negatively correlated with weight-for-age z-score (P b .001) and BMI (both Data are shown as mean ± SD, median (interquartile range), or n (%). All baseline anthropometric characteristics are not statistically different between treatment arms (P N .15). Abbreviation: US/LS, Upper-to-lower segment. ⁎ Weight-for-age z-score, height-for-age z-score, and BMI-for-age z-score are not available for individuals N20 years of age. † Weight-for-height z-score is not available for individuals ≥120.5 cm. ‡ Reduced upper-to-lower segment ratio defined as b1.5 for 0 to 1 year, b1.4 for 1 to 2 years, b1.3 for 2 to 3 years, b1.2 for 3 to 4 years, b1.1 for 4 to 5 years, b1.0 for 5 to 6 years, b0.95 for 6 to 7 years, b0.90 for 7 to 8 years, and b0.85 for N8 years.
Figure 3
Gender differences. Gender differences in family history of aortic surgery, neurodevelopmental history, measurable (mild or more) mitral valve regurgitation, and MVP. Family history of aortic surgery was restricted to subjects who indicated a family history of MFS. **P b .01, ***P b .001.
raw and BMI-for-age z-score, P b .001). No other significant associations were identified.
Family history
Data on family history were available for all but 24 subjects. Among subjects with available data, 62% (n = 360) had a positive family history of MFS, a characteristic that showed no association with age at randomization (positive family history 11.0 ± 6.8 years of age, no family history 11.6 ± 5.7 years of age, P = .3). Of note, among those with a positive family history, 56% had a family member with aortic surgery, and 32% had a family member with a history of aortic dissection (Table II) . Those with a positive family history also had slightly lower median aortic root diameter z-scores (3.9 vs 4.2, P b .001) and were less likely to meet major criteria in the skeletal system (41% vs 59%, P b .001). No other significant associations were identified.
FBN1 mutation status
The frequency of FBN1 testing varied widely by site (range 19%-96%), and FBN1 mutation status was unknown (FBN1 testing not done) in 56% of the randomized subjects, precluding robust analysis. FBN1 mutation status was associated with age at randomization (presence of FBN1 mutation 9.3 ± 5.6 years, absence of FBN1 mutation 12.8 ± 6.5 years, and FBN1 mutation status unknown 12.0 ± 6.4 years, P b .001). Among those with FBN1 testing, (n = 268), 71% had a defined FBN1 mutation, and 29% did not.
Ectopia lentis was more likely in subjects with unknown FBN1 status (55% vs 39% in subjects with a documented mutation and 42% in subjects without a mutation, age-adjusted P = .001). Subjects with a documented mutation were less likely than those without a mutation to have a family history of MFS (46% vs 64%, age-adjusted P = .002). No other significant associations were identified.
Discussion
We have successfully enrolled a very large cohort of pediatric and young adult patients with MFS from 21 international sites into this trial comparing cardiovascular outcomes in subjects randomized to receive atenolol or losartan. This cohort is different from most previously published large series of MFS patients [15] [16] [17] because of the range of age (6 months-25 years) and aortic root diameter z-score requirement for enrollment. The high percentage of subjects b18 years of age in this large cohort is novel.
With a few exceptions, the prevalence rates of the major and minor Ghent criteria were similar in our cohort compared with previously published series. By study design, all subjects had aortic root dilation and, therefore, met major Ghent criteria for the cardiovascular system. Older studies reported a higher prevalence of ectopia lentis of 60% to 70%, probably as result of selection bias; the prevalence of ectopia lentis in our series (48%) was similar to recently published large series (47%-54%). [15] [16] [17] Imaging for dural ectasia was available in only 95 subjects (16%), and the prevalence was lower in our cohort compared with previous reports (34% vs 63%-92%). 1 The prevalence of striae was similar (44% vs 47%), 16 but pulmonary involvement was lower compared with published reports (3% vs 4%-15%). 
Figure 4
Differences by age at randomization. Prevalence of major Ghent criteria in the skeletal, dura, and ocular organ systems; number of major Ghent criteria met; and involvement of pulmonary and skin organ systems by age at randomization quartiles. **P b .01, ***P b .001.
Older subjects in this trial were more likely to exhibit more major and minor manifestations than younger subjects, but the prevalence of ectopia lentis was not dependent on age, consistent with the concept that ectopia lentis is most commonly detected at a young age in MFS. 18 Similarly, aortic root diameter z-score did not vary with age in our cohort of children and young adults selected for moderate to severe aortic dilation. Although a selection bias cannot be completely excluded, the absence of variation in aortic root diameter z-score with age in our cross-sectional sample is consistent with previous longitudinal studies that have shown that aortic root diameter z-score is stable (z-score change per year close to 0), at least in young individuals with MFS. 19 It is important to emphasize that, in growing individuals, the aortic root continues to enlarge despite a stable z-score. Subjects with higher aortic root diameter z-scores were more likely to have additional cardiovascular involvement-MVP and/or dilation of the main pulmonary artery.
That 60% of our cohort is male is intriguing, given that MFS is an autosomal dominant disorder and a balanced gender ratio is expected. The male predominance was present throughout the screening process including the initial medical record review, suggesting that the gender ratio reflected the general Marfan population, but the reason for this is unclear. Several studies in children and adults have also shown a male predominance (54%-60%). [15] [16] [17] 20 Mitral valve prolapse and measurable (mild or more) MR were more common in females in our cohort. In contrast, Detaint et al 20 found no gender differences in MVP or MR among 965 probands with pathogenic FBN1 mutations, but their cohort had a median age at diagnosis of 22 years, leaving open the possibility of an increased risk for MVP/MR in younger females. Of note, Detaint et al also found that men presented earlier and with more severe aortic dilation and related complications compared with the women. Similar trends of earlier and more severe aortic disease are observed in male Fbn1-deficient mice (personal communication, Harry C. Dietz, MD, 2012). However, aortic root diameter z-score was not dependent on gender in our randomized cohort. Thus, more severe disease in males cannot completely account for the greater proportion of males in the overall MFS population.
Hofman et al 21 evaluated the neurodevelopmental status and cognitive ability of 30 consecutive schoolaged children with MFS (70% male) and found ≥1 neuropsychologic deficits-learning disability, attention deficit disorder with or without hyperactivity, neuromaturational immaturity, and verbal performance discrepancy-in half of them (33% of the girls and 62% of the boys). Neurodevelopmental issues were more common in males in our cohort, but our estimates of prevalence were based on medical history and not on the results of formal testing. Whether the male predilection is specific for MFS or reflective of general population trends is unclear; further investigation with formal neuropsychologic testing and long-term follow-up is warranted.
Limitations
The study design only included individuals with at least moderate aortic root dilation and excluded patients at the extremes of the spectrum of aortic disease in MFS. Patients with aortic root diameter z-scores ≤3 and those with previous or impending aortic surgery were excluded. Although the randomized subjects were well characterized, the screening process did not include detailed data collection on all screened patients as this was beyond the scope of the study. Therefore, a robust comparison between the randomized subjects and the screened population was not feasible.
In summary, we have characterized the largest cohort of pediatric and young adult patients with MFS. We found that aortic root z-score did not vary with age and was not dependent on gender. Among those with a family history of MFS, a family history of aortic surgery was more common in females.
The very high consent rate among eligible subjects is notable. The clinical profile of the cohort is representative of patients in this population with moderate to severe aortic root dilation. As expected with randomization, baseline demographic, clinical, and anthropometric characteristics of the study cohort are not different between treatment groups. As such, our multicenter trial is in an excellent position to evaluate the efficacy and safety of atenolol and losartan in young patients with MFS and to determine if the benefit of losartan in the mouse model of MFS translates to humans. The high percentage of young subjects with relatives who have had aortic dissection or surgery illustrates the need for more definitive therapy. We expect that the results of the study and the wealth of systematic data collected will make an important contribution to the management of individuals with MFS. 
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